 - For participants to the Phase 1b Combination part: Diagnosis of locally advanced or metastatic CRC which has been previously treated with more than 2 regimens for the following treatment: fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an angiogenesis inhibitor therapy, and an anti-epidermal growth factor receptor therapy if RAS wild-type tumor and is appropriate for TAS-102 therapy. 